de Boer, I. H. et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 305, 2532–2539 (2011).

Article  PubMed  PubMed Central  Google Scholar 

de Boer, I. H., Group DER. Kidney disease and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 37, 24–30 (2014).

Article  PubMed  Google Scholar 

Afkarian, M. et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA 316, 602–610 (2016).

Article  PubMed  PubMed Central  Google Scholar 

Koye, D. N., Magliano, D. J., Nelson, R. G. & Pavkov, M. E. The global epidemiology of diabetes and kidney disease. Adv. Chronic Kidney Dis. 25, 121–132 (2018).

Article  PubMed  Google Scholar 

Agrawal, L. et al. Intensive glycemic control improves long-term renal outcomes in type 2 diabetes in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care 42, e181–e182 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Agrawal, L. et al. Observation on renal outcomes in the Veterans Affairs Diabetes Trial. Diabetes Care 34, 2090–2094 (2011).

Article  PubMed  PubMed Central  Google Scholar 

Lewis, E. J., Hunsicker, L. G., Bain, R. P. & Rohde, R. D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med. 329, 1456–1462 (1993).

Article  CAS  PubMed  Google Scholar 

Lewis, E. J. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345, 851–860 (2001).

Article  CAS  PubMed  Google Scholar 

Brenner, B. M. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861–869 (2001).

Article  CAS  PubMed  Google Scholar 

Fried, L. F. et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N. Engl. J. Med. 369, 1892–1903 (2013).

Article  CAS  PubMed  Google Scholar 

Parving, H. H. et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N. Engl. J. Med. 367, 2204–2213 (2012).

Article  CAS  PubMed  Google Scholar 

Mann, J. F. et al. Avosentan for overt diabetic nephropathy. J. Am. Soc. Nephrol. 21, 527–535 (2010).

Article  CAS  PubMed  PubMed Central  Google Scholar 

de Zeeuw, D. et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N. Engl. J. Med. 369, 2492–2503 (2013).

Article  PubMed  PubMed Central  Google Scholar 

Packham, D. K. et al. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J. Am. Soc. Nephrol. 23, 123–130 (2012).

Article  CAS  PubMed  Google Scholar 

The E-KCG. et al. Empagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 388, 117–127 (2023).

Article  Google Scholar 

Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295–2306 (2019).

Article  CAS  PubMed  Google Scholar 

Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383, 1436–1446 (2020).

Article  CAS  PubMed  Google Scholar 

Bakris, G. L. et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N. Engl. J. Med. 383, 2219–2229 (2020).

Article  CAS  PubMed  Google Scholar 

Heerspink, H. J. L. et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet 393, 1937–1947 (2019).

Article  CAS  PubMed  Google Scholar 

International Diabetes Federation. IDF Diabetes Atlas, 10th edn. https://www.diabetesatlas.org (2021).

Menke, A., Casagrande, S., Geiss, L. & Cowie, C. C. Prevalence of and trends in diabetes among adults in the United States, 1988–2012. JAMA 314, 1021–1029 (2015).

Article  CAS  PubMed  Google Scholar 

Jager, K. J. et al. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int. 96, 1048–1050 (2019).

Article  PubMed  Google Scholar 

Toppe, C. et al. Decreasing cumulative incidence of end-stage renal disease in young patients with type 1 diabetes in Sweden: a 38-year prospective nationwide study. Diabetes Care 42, 27–31 (2019).

Article  PubMed  Google Scholar 

Gregg, E. W., Hora, I. & Benoit, S. R. Resurgence in diabetes-related complications. JAMA 321, 1867–1868 (2019).

Article  PubMed  Google Scholar 

Narres, M. et al. Incidence and relative risk of renal replacement therapy in people with and without diabetes between 2002 and 2016 in a German region. Diabetologia 63, 648–658 (2020).

Article  PubMed  Google Scholar 

Koye, D. N. et al. Trends in incidence of ESKD in people with type 1 and type 2 diabetes in Australia, 2002–2013. Am. J. Kidney Dis. 73, 300–308 (2019).

Article  PubMed  Google Scholar 

Wu, H. et al. Trends in kidney failure and kidney replacement therapy in people with diabetes in Hong Kong, 2002–2015: a retrospective cohort study. Lancet Reg. Health West Pac. 11, 100165 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Harding, J. L., Pavkov, M. E., Magliano, D. J., Shaw, J. E. & Gregg, E. W. Global trends in diabetes complications: a review of current evidence. Diabetologia 62, 3–16 (2019).

Article  PubMed  Google Scholar 

Afkarian, M. et al. Kidney disease and increased mortality risk in type 2 diabetes. J. Am. Soc. Nephrol. 24, 302–308 (2013).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fox, C. S. et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 380, 1662–1673 (2012).

Article  PubMed  PubMed Central  Google Scholar 

Wen, C. P. et al. Diabetes with early kidney involvement may shorten life expectancy by 16 years. Kidney Int. 92, 388–396 (2017).

Article  PubMed  Google Scholar 

Fioretto, P. & Mauer, M. Histopathology of diabetic nephropathy. Semin. Nephrol. 27, 195–207 (2007).

Article  PubMed  PubMed Central  Google Scholar 

Fiorentino, M. et al. Renal biopsy in patients with diabetes: a pooled meta-analysis of 48 studies. Nephrol. Dial. Transpl. 32, 97–110 (2017).

CAS  Google Scholar 

Fioretto, P. et al. Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 39, 1569–1576 (1996).

Article  CAS  PubMed  Google Scholar 

Jin, Q. et al. Nonalbuminuric diabetic kidney disease and risk of all-cause mortality and cardiovascular and kidney outcomes in type 2 diabetes: findings from the Hong Kong Diabetes Biobank. Am. J. Kidney Dis. 80, 196–206 e1 (2022).

Article  CAS  PubMed  Google Scholar 

Nosadini, R. et al. Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate. Diabetes 49, 476–484 (2000).

Article  CAS  PubMed  Google Scholar 

Fioretto, P., Steffes, M. W., Sutherland, D. E., Goetz, F. C. & Mauer, M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N. Engl. J. Med. 339, 69–75 (1998).

Article  CAS  PubMed  Google Scholar 

Scholtes, R. A. et al. Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors. Nephrology 26, 377–390 (2021).

Article  CAS  PubMed  Google Scholar 

Scholtes, R. A. et al. Kidney hemodynamic effects of angiotensin receptor blockade, sodium-glucose cotransporter-2 inhibition alone, and their combination: a crossover randomized trial in people with type 2 diabetes. Circulation 146, 1895–1897 (2022).

Article  CAS  PubMed  Google Scholar 

Romero, C. A., Orias, M. & Weir, M. R. Novel RAAS agonists and antagonists: clinical applications and controversies. Nat. Rev. Endocrinol. 11, 242–252 (2015).

Article  CAS  PubMed  PubMed Central